← ireadpaper · 顶刊中的公共政策研究

谁从药品价格管制中受益?来自印度的证据

Who benefits from pharmaceutical price controls? Evidence from India
Journal of Public Economics · 2025 · Emma Boswell Dean

中文摘要

本研究考察中等收入国家情境下药品价格管制的影响,重点关注印度药品价格上限政策的一次实施。研究发现,短期内,价格管制导致直接受影响产品及其竞争产品的价格下降,并提高了高质量产品的市场份额。然而,价格管制实施后,低价企业更有可能退出受价格管制的市场,且在价格管制力度更强的市场中,受管制产品的销量有所下降。该法规带来的益处对重视质量的消费者最大,而其弊端则主要影响价格敏感型消费者。

Abstract

This study examines the impacts of pharmaceutical price controls in a middle-income country setting, focusing on an implementation of pharmaceutical price ceilings in India. In the short-term, it finds that price controls led to declining prices for directly-impacted and competing products and increased market share for high-quality products. However, after price controls were implemented, low-priced firms were more likely to exit price-controlled markets and sales of price-controlled products declined in markets with stronger price controls. The benefits of the legislation were largest for quality-sensitive consumers, while the downsides most affected price-sensitive consumers.
在 ireadpaper 查看全部 →